According to Fortune Business Insights, the U.S. Oncology Drugs Market size was valued at USD 87.04 billion in 2023 and is projected to grow at a CAGR of 9.9% during the forecast period of 2024–2032. Based on this growth rate and the 2023 market value, the industry is expected to witness substantial expansion through 2032.
Market Overview
The U.S. oncology drugs market is experiencing considerable growth due to the increasing burden of cancer and continuous pharmaceutical innovation.
According to the report, data from the Centers for Disease Control and Prevention indicated that approximately 1.60 million new cancer cases were reported in the United States in 2020, with the number projected to reach approximately 1.96 million by 2030.
This increasing disease burden highlights the need for advanced cancer treatment solutions.
Additionally, rising drug approvals, growing availability of biosimilars, and increasing investments in oncology research are contributing to market development.
However, high treatment costs, adverse drug reactions, and stringent regulatory requirements remain important challenges for pharmaceutical manufacturers.
For detailed market insights: https://www.fortunebusinessinsights.com/u-s-oncology-drugs-market-108499
Market Trends
Increasing Adoption of Artificial Intelligence in Oncology Drug Development
Artificial intelligence is becoming an important technology in oncology pharmaceutical research.
Companies are incorporating AI and machine learning to analyze biological information, identify potential drug candidates, and accelerate pharmaceutical development.
In February 2023, Tempus announced a strategic collaboration with Pfizer to advance AI-driven therapeutic development.
Similarly, CytoReason expanded its partnership with Pfizer in September 2022 to support drug development through artificial intelligence technology.
Growing Demand for Targeted Cancer Therapies
Targeted cancer treatments are gaining importance because they focus on specific molecular characteristics associated with malignant cells.
Increasing clinical trials, regulatory approvals, and pharmaceutical innovations are encouraging the development of targeted oncology medications.
Rising Interest in Biosimilar Cancer Medicines
The introduction of biosimilar oncology medications is creating opportunities to expand treatment availability.
These products may provide alternatives to established biological medicines and contribute to competition within the pharmaceutical industry.
Market Drivers
Increasing Prevalence of Cancer
The growing incidence of cancer is a major factor driving the U.S. oncology drugs market.
Breast cancer, lung cancer, colorectal cancer, and prostate cancer represent important treatment areas.
According to figures cited in the report from the National Cancer Institute, approximately 300,590 new breast cancer cases were expected in the United States in 2023.
Rising Pharmaceutical Research and Development Investments
Pharmaceutical manufacturers are investing in innovative oncology medications to improve treatment effectiveness and expand their product portfolios.
Research activities involving monoclonal antibodies, targeted therapies, and immunotherapies are supporting the development of new treatment options.
Increasing Regulatory Approvals
The approval of new cancer medications contributes to the availability of innovative therapies.
For example, in May 2023, AbbVie received U.S. FDA approval for EPKINLY (epcoritamab-bysp), a bispecific antibody for certain adults with relapsed or refractory diffuse large B-cell lymphoma.
Growing Awareness of Cancer Treatment
Increasing cancer awareness and improvements in diagnostic practices are supporting demand for oncology medications.
Earlier diagnosis and greater access to specialized treatment services can contribute to increased utilization of cancer therapies.
Market Segmentation
The U.S. oncology drugs market is segmented by drug class, therapy, indication, dosage form, and distribution channel.
By Drug Class
The market includes:
- Cytotoxic Drugs: Alkylating agents, antimetabolites, and other chemotherapy medications.
- Targeted Drugs: Monoclonal antibodies and other targeted treatments.
- Hormonal Drugs: Medications used for hormone-sensitive cancers.
- Other Drugs: Additional pharmaceutical treatments used in oncology.
The targeted drugs segment accounted for a significant market share in 2022, supported by increasing adoption, clinical trials, and regulatory approvals.
By Therapy
The market is divided into chemotherapy, targeted therapy, and immunotherapy.
Targeted therapy held a significant share in 2022 due to increasing demand for treatments directed at specific cancer-related biological targets.
Immunotherapy is also expected to experience substantial growth as pharmaceutical manufacturers introduce advanced cancer treatment solutions.
By Indication
The market includes lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, and other cancers.
The lung cancer segment held the largest market share in 2022, influenced by cancer incidence, smoking-related risks, and aging populations.
Meanwhile, the breast cancer segment demonstrated strong growth potential due to increasing diagnoses and therapeutic developments.
By Dosage Form
The market is segmented into solid, liquid, and injectable formulations.
Injectable oncology drugs held the largest market share in 2022, supported by demand for effective drug delivery systems.
Solid dosage forms, including tablets and capsules, are projected to experience rapid growth during the forecast period.
By Distribution Channel
The market includes hospital pharmacies and retail and online pharmacies.
Hospital pharmacies accounted for the largest market share in 2022 due to the frequent administration and prescription of cancer medications in hospital settings.
Online pharmacies are expected to experience considerable growth due to convenience and increasing digital adoption.
Key Players in the U.S. Oncology Drugs Market
Major companies operating in the market include:
- Genentech, Inc. – A U.S.-based biotechnology company developing innovative cancer therapies.
- F. Hoffmann-La Roche Ltd. – A pharmaceutical manufacturer with an extensive oncology portfolio.
- Novartis AG – Develops targeted cancer medications and innovative pharmaceutical therapies.
- Pfizer Inc. – Invests in oncology research, pharmaceutical development, and strategic acquisitions.
- Bristol Myers Squibb Company – Focuses on cancer medicines, including immunotherapy treatments.
- GlaxoSmithKline plc – Expands its oncology portfolio through pharmaceutical development and acquisitions.
- Eli Lilly and Company – Develops pharmaceutical treatments across multiple therapeutic areas, including oncology.
- AstraZeneca – Invests in oncology research and targeted cancer therapies.
- Merck & Co., Inc. – Develops cancer treatments and participates in oncology research collaborations.
- Sanofi – Maintains pharmaceutical research activities across several therapeutic areas.
Regional Analysis
United States
The United States represents the complete geographical scope of this market report.
The country has an established pharmaceutical industry, advanced healthcare infrastructure, and significant investment in oncology research.
Increasing cancer incidence and the availability of specialized cancer treatment facilities are supporting demand for oncology medications.
The presence of major pharmaceutical manufacturers, biotechnology companies, and clinical research organizations further strengthens market development.
Hospital pharmacies remain an important distribution channel, while retail and online pharmacies are gaining attention.
The report does not provide separate numerical market shares for individual U.S. states or regions.
Competitive Landscape
The U.S. oncology drugs market is moderately fragmented, with established pharmaceutical manufacturers and emerging biotechnology companies competing through product innovation and strategic partnerships.
Leading companies are focusing on clinical trials, regulatory approvals, mergers, acquisitions, and advanced therapeutic development.
In March 2023, Pfizer announced its acquisition of Seagen to strengthen its oncology portfolio.
In July 2022, GlaxoSmithKline acquired Sierra Oncology to expand its oncology product portfolio and commercial capabilities.
Additionally, Merck and KLUS Pharma announced a collaboration in December 2022 to develop investigational antibody-drug conjugates for cancer treatment.
These developments highlight the importance of pharmaceutical innovation and strategic partnerships in the competitive environment.
Future Outlook
The U.S. oncology drugs market is expected to maintain strong growth through 2032, supported by rising cancer incidence, technological advancements, and pharmaceutical research activities.
Artificial intelligence, targeted therapies, and immunotherapy are expected to influence future cancer treatment development.
Increasing clinical trials and regulatory approvals may further expand the availability of innovative oncology medications.
The growing adoption of biosimilars could also improve competition and create opportunities for more accessible treatment options.
However, high pharmaceutical costs, treatment-related adverse effects, and regulatory requirements will continue to influence industry development.
Companies focusing on research innovation, effective treatment delivery, and strategic collaborations are expected to remain important market participants.
Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-oncology-drugs-market-108499
Conclusion
The U.S. oncology drugs market is positioned for substantial expansion, supported by increasing cancer prevalence, advanced pharmaceutical research, and rising demand for innovative treatment solutions.
With a market valuation of USD 87.04 billion in 2023 and a projected CAGR of 9.9% during 2024–2032, the industry offers significant opportunities for pharmaceutical manufacturers.
Targeted drugs, immunotherapy, and advanced injectable formulations are influencing market development.
Continued innovation, regulatory approvals, and strategic partnerships are expected to shape the future of cancer treatment in the United States.
Frequently Asked Questions (FAQs)
1. How Big Is the U.S. Oncology Drugs Market?
Fortune Business Insights states that the U.S. oncology drugs market was valued at USD 87.04 billion in 2023 and is projected to grow significantly through 2032.
2. At What CAGR Is the U.S. Oncology Drugs Market Expected to Grow During 2024–2032?
The market is expected to exhibit a CAGR of 9.9% during the forecast period of 2024–2032.
3. Which Segment Dominates the U.S. Oncology Drugs Market?
The targeted drugs segment accounted for a significant share of the market in 2022, supported by increasing adoption, clinical trials, and new product approvals.
4. Who Are the Major Players in the U.S. Oncology Drugs Market?
Major players include Genentech, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, and GlaxoSmithKline plc.
5. What Are the Key Trends Driving the U.S. Oncology Drugs Market?
Major market trends include:
- Increasing adoption of artificial intelligence and machine learning in oncology drug development.
- Growing demand for targeted therapies and immunotherapy treatments.
- Rising pharmaceutical collaborations, regulatory approvals, and development of biosimilar cancer medications.
Curious About Japan’s Market? Explore the Latest U.S. Oncology Drugs Market Insights
Comments